Riskpilot← Back to searchSign inGet full accessProgyn Oy
OYDissolvedY-tunnus 2048911-4Runeberginkatu 30-A14Medical specialists activities · NACE 8622Est. 20061 employees
Revenue 2025
EUR 262K
0% vs 2024
EBITDA margin
49.1%
-8% vs 2024
Equity ratio
99.0%
Financial strength
Net profit 2025
EUR 147K
+8% vs 2024
| Revenue | EUR 262K | +0% |
| EBITDA | EUR 129K | -8% |
| Net profit | EUR 147K | +8% |
| Total assets | EUR 1,1M | +0% |
| Equity | EUR 1,1M | +0% |
| Employees | 1 | — |
Legal name
Progyn Oy
Y-tunnus number
2048911-4
Legal form
Osakeyhtiö
NACE code
8622 · Medical specialists activities
Founded
17. heinäkuuta 2006
Share capital
EUR 8 000
Employees
1 (FTE)
VAT registered
No
Audit selected
No
Last report
2025-08-31
Financial year
January – December
Signatory rights
Hallituksen puheenjohtaja ja toimitusjohtaja kumpikin yksin ja hallituksen jäsenet kaksi yhdessä
Company purpose
Yhtiön toimiala on tuottaa terveydenhuoltopalveluja ja harjoittaa tutkimus-, julkaisu- ja koulutustoimintaa. Yhtiö voi hallita, ostaa, myydä ja vuokrata huoneistoja sekä kiinteää ja irtainta omaisuutta ja harjoittaa arvopaperikauppaa.
Address
Runeberginkatu 30-A14
Phone
+3580505841749
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 239 | 238 | 222 | 262 | 262 |
| Staff expenses | −51 | −51 | −51 | −52 | −52 |
| EBITDA | 131 | 124 | 97 | 141 | 129 |
| Depreciation & amort. | −0 | −1 | −0 | −0 | −0 |
| EBIT | 131 | 123 | 97 | 141 | 129 |
| Net financials | 37 | 8 | 36 | 31 | 56 |
| Profit before tax | 168 | 131 | 133 | 172 | 185 |
| Tax | 29 | 28 | 28 | 36 | 38 |
| Net profit | 139 | 103 | 105 | 136 | 147 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 056 | 1 069 | 1 087 | 1 145 | 1 144 |
| Equity | 1 047 | 1 066 | 1 086 | 1 136 | 1 132 |
| Long-term debt | — | — | 0 | 0 | 0 |
| Short-term debt | 10 | 3 | 1 | 9 | 12 |
| Total debt | 10 | 3 | 1 | 9 | 12 |
EBITDA margin
49.1%
This company
15.8%
Market median
+211% vs market
20212025
Equity ratio
99.0%
This company
38.2%
Market median
+159% vs market
20212025
Return on equity
13.0%
This company
18.4%
Market median
+29% vs market
20212025
Net profit margin
56.1%
This company
8.1%
Market median
+593% vs market
20212025
Asset turnover
0.23×
This company
1.12×
Market median
-79% vs market
20212025
Debt / equity
0.01×
This company
0.62×
Market median
+98% vs market
20212025
- Annual report 2025Filed via PRH / YTJ · Period 2024-09-01 – 2025-08-31
- Annual report 2024Filed via PRH / YTJ · Period 2023-09-01 – 2024-08-31
- Annual report 2023Filed via PRH / YTJ · Period 2022-09-01 – 2023-08-31
- Annual report 2022Filed via PRH / YTJ · Period 2021-09-01 – 2022-08-31
- Annual report 2021Filed via PRH / YTJ · Period 2020-09-01 – 2021-08-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
VP Deputy Chief Executive Officer | Deputy Chief Executive Officer | 2011 |
MH Chief Executive Officer | Chief Executive Officer | 2011 |
| Former (1) | ||
TJ Audit | Audit | 2014 – 2023 |
No data on file.
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Progyn Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Vesa Petri Paukku | Deputy Chief Executive Officer | 0 companies |
| Turo Juhani Koila | Audit | 0 companies |
| Maarit Hannele Paukku | Chief Executive Officer | 0 companies |